Dermamed, Inc.

Agry Med Ltd.

Pharmaderm Research & Development Ltd.

Yosef Rubinstein

Avi Gertner

A pharmaceutical formulation which is adapted particularly for transdermal administration, and which comprises an aqueous emulsion or dispersion including, in addition to the aqueous phase, at least ingredients (a) and (b) of ingredients (a), (b) and (c): (a) as active ingredient, at least one therapeutically active protein or polypeptide; (b) at least one pharmaceutically acceptable emulsifier; (c) an oil phase comprising or consisting essentially of at least one ester of an aliphatic hydroxy compound containing 1-12 carbon atoms and 1-4 alcoholic hydroxy groups with an aliphatic carboxylic acid containing 8-24 carbon atoms and 1-3 carboxylic acid groups; provided that the therapeutic activity of the active ingredient in the formulation is such that the presence or the therapeutic effect of the active ingredient is detectable in the bloodstream within less than two hours after commencing transdermal administration, and further provided that when the active ingredient comprises insulin, the insulin is subjected to a pretreatment under predetermined conditions, prior to incorporation in the formulation.

Formulations comprising therapeutically-active proteins or polypeptides

A pharmaceutical composition for use in the transdermal administration of a medicament to both humans and animals, which composition comprises at least ingredients (1) and (2) of the following ingredients (1), (2) and (3), namely: (1) an effective amount of a medicament adapted for transdermal administration; (2) a transdermally transporting effective amount of a carrier for the medicament, which carrier is selected from semisolids and liquids at ambient temperatures, and which carrier comprises at least one compound selected from esters of C.sub.8-24 fatty acids, pharmaceutically acceptable aliphatic polyhydroxy compounds and non-volatile paraffins; (3) an optional medicament selected from antiinflammatory agents and antihistamines, effective to mitigate any skin-incompatibility characteristic which may otherwise be present. Administration is preferably by means of a matrix which comprises a porous, absorbent, perforate and flexible laminar solid support, having the composition absorbed thereon. The invention includes a device for use in transdermal administration, which comprises such a matrix, preferably included in a multilayer system providing a desired controlled or sustained release pattern for said medicament; as well as apparatus for applying a medicament non-adhesively to the skin of an animal, which comprises a removable enclosure bearing such a matrix or device, the apparatus being arranged for non-invasive mounting onto an animal ear.

Transdermal administration to humans and animals

A non-adhesive matrix for use as a dosage form in the transdermal administration of a medicament to a mammal comprises a porous, non-adhesive, absorbent perforate solid support having absorbed thereon a mixture comprising a medicament adapted for transdermal administration and a pharmaceutically acceptable carrier for the medicament. The carrier consists essentially of at least one compound selected from esters of C.sub.8-24 fatty acids, pharmaceutically acceptable aliphatic polyhydroxy compounds and non-volatile paraffins.

Systems for transdermal administration of medicaments

A technique for administering medicaments in veterinary applications including the steps of applying a medicament transdermally to an animal and non-surgically terminating the application of the medicament at a pre-determined time. There is also provided apparatus for transdermal application of medicaments to animals including a removable enclosure arranged to be non-invasively mounted onto an animal ear.

Growing community of inventors

Nes Ziona, Israel

Yosef Rubinstein